Table 2.

Association of smoking habits with CIN2 and ≥CIN3 among oncogenic HPV DNA–positive women

<CIN2
CIN2*
≥CIN3*
n (%)n (%)n (%)OR (95% CI)n (%)OR (95% CI)
Never1,623 (52)1,255 (56)173 (48)1.0 (reference)195 (39)1.0 (reference)
Former290 (9)195 (9)40 (11)1.5 (1.0 -2.1)55 (11)1.7 (1.2 -2.4)
Current1,212 (39)809 (36)147 (41)1.2 (1.0 -1.6)256 (51)1.7 (1.4 -2.1)
PTrend<0.0005
Never1,623 (52)1,255 (56)173 (48)1.0 (reference)195 (39)1.0 (reference)
Former290 (9)195 (9)40 (11)1.5 (1.0 -2.1)55 (11)1.7 (1.2 -2.4)
Current, <1 pack/d804 (26)560 (25)93 (26)1.1 (0.9 -1.5)151 (30)1.5 (1.2 -2.0)
Current, 1 to <2 packs/d376 (12)231 (10)52 (14)1.4 (1.0 -2.0)93 (18)2.0 (1.4 -2.7)
Current, ≥2 packs/d21 (1)18 (1)2 (1)0.7 (0.2 -2.9)12 (2)3.3 (1.5 -7.5)
PTrend<0.0005
Never1,623 (52)1,255 (56)173 (48)1.0 (reference)195 (39)1.0 (reference)
Former290 (9)195 (9)40 (11)1.5 (1.0 -2.1)55 (11)1.7 (1.2 -2.4)
Current, <6 y509 (16)358 (16)62 (17)1.1 (0.8 -1.6)89 (18)1.3 (0.9 -1.7)
Current, 6-10 y374 (12)242 (11)41 (11)1.1 (0.8 -1.7)91 (18)2.0 (1.5 -2.8)
Current, ≥11 y328 (10)209 (9)43 (12)1.4 (1.0 -2.0)76 (15)2.1 (1.5 -2.9)
PTrend0.0005
  • NOTE: ORs with 95% CI from multinomial logistic regression models comparing women with a CIN2 or ≥CIN3 diagnosis to women with a <CIN2 diagnosis. Values in bold indicate ORs for which the lower or upper confidence bound does not include 1.00. Includes all women who were oncogenic HPV-positive upon enrollment (i.e. women with all diagnoses: <CIN2, CIN2, ≥CIN3) during the 2-year study period.

  • * Includes all cases diagnosed upon enrollment, during the 2-year follow-up, and at the exit colposcopy.

  • Adjusted for HPV16 DNA positivity and education.